Conmed Corp.
This article was originally published in The Gray Sheet
Executive Summary
Launches Trogard electronic trocar system and a modular instrument system for laparoscopic surgery. The firm says its Trogard system "increases safety and surgeon control by using familiar electrosurgical techniques" to create punctures for instruments rather than mechanical force. The modular instruments allow the surgeon to choose "the type of working tip, the manner of controlling electrosurgery and mode of suction/irrigation control" to be used. The firm says that it does not expect significant revenue from the products during the first quarter of 1993 "because of the necessary length of customer evaluations".
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.